Pharmaceutical Japanese drugmaker Chugai Pharmaceutical (TYO: 4519) said this morning (June 28) that it has obtained approval by the Japanese Ministry of Health, Labor and Welfare (MHLW) for two new products, the first being for HER2-positive inoperable or recurrent breast cancer, for the anti-cancer agent/anti-HER2 humanized monoclonal antibody, Perjeta IV Infusion (pertuzumab [genetical recombination]). 28 June 2013